What is Aardvark Therapeutics, Inc. Common Stock's market cap?

Aardvark Therapeutics, Inc. Common Stock (AARD) has a market capitalization of $124.4M and trades on NASDAQ.

Who are Aardvark Therapeutics, Inc. Common Stock's competitors?

Aardvark Therapeutics, Inc. Common Stock's key competitors include Rhythm Pharmaceuticals, Relmada Therapeutics, Bright Minds Biosciences Inc., and others. These companies compete in similar markets and product categories.

Who does Aardvark Therapeutics, Inc. Common Stock partner with?

Aardvark Therapeutics, Inc. Common Stock's notable partners include Decheng Capital.

What subsidiaries does Aardvark Therapeutics, Inc. Common Stock have?

Aardvark Therapeutics, Inc. Common Stock's subsidiaries include Artisan Therapeutics, Inc., Ardia Therapeutics, Inc..

Where is Aardvark Therapeutics, Inc. Common Stock headquartered?

Aardvark Therapeutics, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.

Aardvark Therapeutics, Inc. Common Stock

AARD

Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases.

Market cap

$124.35M-58.6%

Net income-$69.9M-152%

EPS (diluted)-$3.21+39.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue-EPS-$0.99Miss by $0.12

Read the full report

Next report

Aug 12, 2026 (in a month)

EPS estimate-$0.86

Financials

Q1 2026

Income statement

See full

Revenue-—

Operating income-$22.5M-115%

Net income-$21.6M-132%

EPS (diluted)-$0.99-39.4%

Balance sheet

See full

Cash & equivalents$62.4M+136%

Total debt$336.0K-53.7%

Total equity$87.0M-42.3%

Total assets$98.6M-37.2%

Cash flow

See full

Operating cash flow-$18.9M-65.7%

Valuation & ratios

Valuation

See full

Market cap$124.35M-58.6%

Enterprise value$62.25M-77.4%

Returns & leverage

See full

Return on equity-58.8%—

Debt / equity0×0.0×

Current ratio8.1×-17.8×

Competitors

By market cap

AbbVie$444.60B+35.8%

Rhythm Pharmaceuticals, Inc.$7.6B+92.2%

Viking Therapeutics$4.5B+48.9%

Relmada Therapeutics, Inc.$726.5M+3,982%

Bright Minds Biosciences$688.8M+273%

Aardvark Therapeutics, Inc. Common Stock$124.4M-58.6%

Palatin Technologies$19.2M—

Adial Pharmaceuticals$5.6M+44.4%

By revenue growth

Rhythm Pharmaceuticals, Inc.+58.7%

AbbVie+9.5%

By net margin

AbbVie5.79%—

Rhythm Pharmaceuticals, Inc.-93.33%—

Profile

Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases. The company primarily targets Bitter Taste Receptors (TAS2Rs) in the gut to induce the secretion of endogenous signaling molecules like CCK and GLP-1, aiming to alleviate hunger and treat conditions such as Prader-Willi Syndrome and obesity.

Competitive position

Aardvark is a pioneer in targeting TAS2Rs for hunger-associated conditions, currently managing a voluntary clinical pause for its lead candidate while maintaining a proprietary position in gut-restricted small molecules.

GeographiesUnited States, Canada, United Kingdom, South Korea, Australia

Customer segmentsRare disease patients, Metabolic disorder patients

Business modelR&D intensive, Biopharmaceutical drug development

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Raw material suppliers

CustomersSpecialty pharmacies, Hospitals, Healthcare providers, Third-party payors

CountryUnited States of America

Listed2025

CEOTien-Li Lee

Websiteaardvarktherapeutics.com

FilingsSEC EDGAR

Questions, answered.

What is Aardvark Therapeutics, Inc. Common Stock's market cap?: Aardvark Therapeutics, Inc. Common Stock (AARD) has a market capitalization of $124.4M and trades on NASDAQ.
Who are Aardvark Therapeutics, Inc. Common Stock's competitors?: Aardvark Therapeutics, Inc. Common Stock's key competitors include Rhythm Pharmaceuticals, Relmada Therapeutics, Bright Minds Biosciences Inc., and others. These companies compete in similar markets and product categories.
Who does Aardvark Therapeutics, Inc. Common Stock partner with?: Aardvark Therapeutics, Inc. Common Stock's notable partners include Decheng Capital.
What subsidiaries does Aardvark Therapeutics, Inc. Common Stock have?: Aardvark Therapeutics, Inc. Common Stock's subsidiaries include Artisan Therapeutics, Inc., Ardia Therapeutics, Inc..
Where is Aardvark Therapeutics, Inc. Common Stock headquartered?: Aardvark Therapeutics, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.